Antiviral drugs in influenza: An adjunct to vaccination in some situations

Prescrire International

Volumn 15, Issue 81, 2006, Pages 21-30

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INFLUENZA VACCINE; MEMANTINE; METHOTREXATE; OSELTAMIVIR; PHENOTHIAZINE DERIVATIVE; PLACEBO; PROBENECID; RIMANTADINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZANAMIVIR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADJUVANT THERAPY; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; AVIAN INFLUENZA; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DEATH; DELIRIUM; DOSE RESPONSE; DRUG CHOICE; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIDEMIC; GASTROINTESTINAL DISEASE; GUILLAIN BARRE SYNDROME; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEPATITIS; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INJECTION PAIN; LEG EDEMA; LIVEDO RETICULARIS; MALAISE; MENTAL DISEASE; META ANALYSIS; MYALGIA; NAUSEA; NERVOUSNESS; NEURITIS; NEUROLOGIC DISEASE; NIGHTMARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TERATOGENICITY; URINE RETENTION; VIRUS RESISTANCE; VIRUS VIRULENCE; VOMITING; XEROSTOMIA;

ACETAMIDES; AMANTADINE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; GUANIDINES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PREGNANCY; PYRANS; SIALIC ACIDS; TREATMENT OUTCOME;

EID: 31944444952     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Prescrire Editorial Staff "Zanamivir. Still no evidence of benefit" Prescrire Int 2001; 10 (56): 175-177.
2. Prescrire Editorial Staff "Oseltamivir" Prescrire Int 2003; 12 (65): 85-88.
3. Prescrire Rédaction "oseltamivir: remboursable pour certains patients à risque" Rev Prescrire 2004; 24 (256): 823.
4. Dolin R "Influenza". In: Braunwald E et al. "Harrison's principles of internal medicine" 15th ed, McGraw-Hill, New York 2001: 1125-1130.
5. "Influenza". In: "Control of communicable diseases manual" 17th ed., American Public Health Association, Washington 2000: 270-276.
6. Turner D et al. "Systematic review and economic decision modelling for the prevention and treatment of influenza A and B" Health Technol Assess 2003; 7 (35): 286 pages.
7. World Health Organization "Vaccins antigrippaux" Wkly Epidemiol Rec/ Rel Épidémiol Hebd 2002; 77 (28): 230-240.
8. Nicholson KG et al. "Influenza" Lancet 2003; 362: 1733-1745.
9. Palese P "Influenza: old and new threats" Nat Med 2004; 10 (12 suppl.): 582-587.
10. Centers for Disease Control and Prevention "Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)" MMWR 2005; 54 (early release): 1-41 + Erratum in: MMWR 2005; 54 (early release): 1 page.
11. Frank AL et al. "Patterns of shedding of Myxoviruses and Paramyxoviruses in children" J Infect Dis 1981; 144 (5): 433-441.
12. Klimov AI et al. "Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis" J Infect Dis 1995; 172: 1352-1355.
13. Englund JA et al. "Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults" Clin Infect Dis 1998; 26: 1418-1424.
14. Boivin G et al. "Prolonged excretion of amantadine-resistant influenza A virus quasi species after cessation of antiviral therapy in an immunocompromised patient" Clin Infect Dis 2002; 34: e23-e25.
15. Call SA et al. "Does this patient have influenza?" JAMA 2005; 293 (8): 987-997.
16. Boivin G et al. "Predicting influenza infections during epidemics with use of a clinical case definition" Clin Infect Dis 2000; 31: 1166-1169.
17. Monto AS et al. "Clinical signs and symptoms predicting influenza infection" Arch Intern Med 2000; 160: 3243-3247.
18. Zambon M et al. "Diagnosis of influenza in the community" Arch Intern Med 2001; 161: 2116-2122.
19. Walsh EE et al. "Clinical features of influenza A virus infection in older hospitalised persons" J Am Geriatr Soc 2002; 50 (9): 1498-1503.
20. Nicholson KG et al. "Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden" BMJ 1997; 315: 1060-1064.
21. Mäkelä MJ et al. "Viruses and bacteria in the etiology of the common cold" J Clin Microbiol 1998; 36 (2): 539-542.
22. Zambon MC et al. "Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study" Lancet 2001; 358: 1410-1416.
23. Jefferson T "How to deal with influenza?" BMJ 2004; 329: 633-634.
24. Hansen L et al. "Effect of antiviral medications for early treatment of influenza in adults". In: "Clinical evidence" 12th ed., BMJ Group, London 2004: 1095-1102.
25. Uyeki TM et al. "Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza" Pediatr Infect Dis J 2003; 22 (2): 164-176.
26. Prescrire Rédaction "Vacciner les enfants contre la grippe" Rev Prescrire 2003; 23 (245): 852-856.
27. Principi N and Esposito S "Are we ready for universal influenza vaccination in paediatrics?" Lancet Infect Dis 2004; 4: 75-83.
28. Prescrire Editorial Staff "Pregnancy and influenza vaccination" Prescrire Int 2004; 13 (69): 30.
29. "Calendrier vaccinal 2005. Avis du Conseil supérieur d'hygiène publique de France (Section des maladies transmissibles) 27 May 2005" BEH 2005; (29-30): 142-147.
30. Prescrire Rédaction "Vacciner les sujets âgés contre la grippe" Rev Prescrire 2000; 20 (205): 296-297.
31. Prescrire Rédaction "Vacciner contre la grippe les personnel âgées vivant à domicile" Rev Prescrire 2003; 23 (244): 775.
32. Smith SA and Poland GA "Use of influenza and pneumococcal vaccines in people with diabetes" Diabetes Care 2000; 23 (1): 95-108.
33. Heymann AD et al. "Reduced hospitalisations and death associated with influenza vaccination among patients with and without diabetes" Diabetes Care 2004; 27 (11): 2581-2584.
34. Jefferson T et al. "Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review" Lancet 2005; 365: 773-780.
35. Gross PA et al. "Effect of cancer chemotherapy on the immune response to influenza virus vaccine: review of published studies" Rev Infect Dis 1985; 7 (5): 613-618.
36. Blumberg EA et al. "The immunogenicity of influenza virus vaccine in solid organ transplant recipients" Clin Infect Dis 1996; 22: 295-302.
37. Tasker SA et al. "Efficacy of influenza vaccination in HIV-infected persons. A randomised double-blind, placebo-controlled trial" Ann Intern Med 1999; 131 (6): 430-433.
38. Duchini A et al. "Influenza infection in patients before and after liver transplantation" Liver Transpl 2000; 6 (5): 531-542.
39. Vichez RA et al. "The pathogenesis and management of influenza virus infection in organ transplant recipients" Transplant Infect Dis 2002; 4 (4): 177-182.
40. Obaro SK et al. "Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children" Lancet Infect Dis 2004; 4: 510-518.
41. Melcher L "Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy" Clin Oncol 2005; 17 (1): 12-15.
42. Salgado CD et al. "Influenza in the acute hospital setting" Lancet Infect Dis 2002; 2: 145-155.
43. Prescrire Rédaction "Grippe: il faut vacciner le personnel des structures de long séjour" Rev Prescrire 1998; 18 (182): 223-224.
44. Prescrire Rédaction "Soignants: se faire vacciner contre la grippe" Rev Prescrire 2000; 20 (209): 603-604.
45. "Influenza vaccines". In: "Martindale The complete drug reference" 34th ed, The Pharmaceutical Press, London 2005: 1620-1621.
46. Palache AM "Influenza vaccines: a reappraisal of their use" Drugs 1997; 54 (6): 841-856.
47. Haber P et al. "Guillain-Barré syndrome following influenza vaccination" JAMA 2004; 292 (20): 2478-2481.
48. Delem A and Jovanovic D "Correlation between rate of infection and preexisting titer of serum antibody as determined by single radial hemolysis during an epidemic of influenza A/Victoria/3/75" J Infect Dis 1978; 137 (2): 194-196.
49. Al-Khayatt R et al. "Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysis" J Hyg 1984; 92: 301-312.
50. Brokstad KA et al. "Parenteral influenza vaccination induces a rapid systemic and local immune response" J Infect Dis 1995; 171: 198-203.
51. Gross PA et al. "Time to earliest peak serum antibody response to influenza vaccine in the elderly" Clin Diagn Lab Immunol 1997; 4 (4): 491-492.
52. McElhaney JE et al. "Immune response to influenza vaccination in institutionalized elderly: effect on different T-cell subsets" Vaccine 1998; 16 (4): 403-409.
53. Ghendon Y "The immune response to influenza vaccines" Acta Virol 1990; 34: 295-304.
54. Oxford JS et al. "The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection" J Hyg 1979; 82: 51-61.
55. Potter CW and Oxford JS "Determinants of immunity to influenza infection in man" Br Med Bull 1979; 35 (1): 69-75.
56. Couch RB and Kasel JA "Immunity to influenza in man" Annu Rev Microbiol 1983; 37: 529-549.
57. Clements ML et al. "Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus" J Clin Microbiol 1986; 24 (1): 157-160.
58. Hirota Y et al. "Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness" Vaccine 1997; 15 (9): 962-967.
59. Neuzil KM et al. "Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience" Pediatr Infect Dis 2001; 20 (8): 733-740.
60. Jefferson T et al. "Amantadine and rimantadine for preventing and treating influenza A in adults" (Cochrane Review). In: "The Cochrane Library" John Wiley and Sons, Chichester 2005; issue 2: 58 pages.
61. Leeming JT et al. "Amantadine hydrochloride and the elderly" BMJ 1969; 1 (639): 313-314.
62. Pettersson RF et al. "Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection" J Infect Dis 1980; 142 (3): 377-383.
63. Schilling M et al. "Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks" Vaccine 1998; 16 (18): 1771-1774.
64. Monto AS et al. "Zanamivir in the prevention of influenza among healthy adults. A randomised controlled trial" JAMA 1999; 282 (1): 31-35.
65. Kaiser L et al. "Short-term treatment with Zanamivir to prevent influenza: results of a placebo-controlled study" Clin Infect Dis 2000; 30: 587-589.
66. Hayden FG et al. "Inhaled zanamivir for the prevention of influenza in families" N Engl J Med 2000; 343 (18): 1282-1289.
67. Monto AS et al. "Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households" J infect Dis 2002; 186: 1582-1588.
68. McGeer AJ et al. "Use of zanamivir to control an outbreak of influenza A in a nursing home" Clin Infect Dis 2000; 31: 318.
69. Hayden FG et al. "Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza" N Engl J Med 1999; 341 (18): 1336-1343.
70. Kashiwagi S et al. "Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza. Placebo-controlled double-blind multicenter phase III trial" (in Japanese) Kassenshogaku Zasski 2000; 74: 1062-1076.
71. Peters PH et al. "Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population" J Am Geriatr Soc 2001; 49: 1025-1031.
72. Welliver R et al. "Effectiveness of oseltamivir in preventing influenza in household contacts. A randomized controlled trial" JAMA 2001; 285 (6): 748-754.
73. Parker R et al. "Experience with oseltamivir in the control of nursing home influenza B outbreak" Can Commun Dis Rep/Rel Mal Transmis Can 2001; 27: 37-40.
74. Shijubo N et al. "Experience with oseltamivir in the control of nursing home influenza A outbreak" Intern Med 2002; 41: 366-370.
75. Bowles SK et al. "Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000" J Am Geriatr Soc 2002; 50: 608-616.
76. Chik KW et al. "Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study" Hong Kong Med J 2004; 10 (2): 103-106.
77. Hayden FG et al. "Management of influenza in households: a prospective, randomised comparison of oseltamivir treatment with or without postexposure prophylaxis" J infect Dis 2004; 189: 440-449.
78. Oxford JS and Galbraith A "Anti influenza virus activity of amantadine" Viral Chemother 1984; 1: 169-254.
79. Govorkova EA et al. "Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza virus" Antimicrobial Agents Chemother 2001; 45 (10): 2723-2732.
80. Leneva IA et al. "Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals" Antimicrobial Agents Chemother 2001; 45 (4): 1216-1224.
81. Ward P et al. "Oseltamivir (Tamifluo) and its potential for use in the event of an influenza pandemic" J Antimicrob Chemother 2005; 55 (suppl. 1): 5-21.
82. Koopmans M et al. "Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands" Lancet 2004; 363: 587-593.
83. Prescrire Redaction "12-4 Patients parkinsoniens. 12-4-5 Patients sous amantadine". In: "Interactions médicamenteuses. Comprendre et décider" 2005; 25 (259 suppl.): 70-71.
84. "Amantadine". In: "Martindale The complete drug reference" 34th ed., The Pharmaceutical Press, London 2005: 1197-1199.
85. Cheer SM and Wagstaff AJ "Zanamivir. An update of its use in influenza" Drugs 2002; 62 (1): 71-106.
86. "Zanamivir". In: "Martindale The complete drug reference" 34th ed., The Pharmaceutical Press, London 2005: 658.
87. Dutkowski R et al. "Safety and pharmacology of oseltamivir in clinical use" Drug Saf 2003; 26 (11): 787-801.
88. "Oseltamivir". In: "Martindale The complete drug reference" 34th ed., The Pharmaceutical Press, London 2005: 651.
89. Kaji M et al. "A side effect of neuraminidase inhibitor in a patient with liver cirrhosis" J Infect Chemother 2005; 11: 41-43.
90. "Tamifluo". In: "Physicians' Desk Reference" Thomson-PDR, Montvale 2005: 2927-2929.
91. Hama R "New type of influenza-related encephalopathy or new adverse drug reaction" 28 February 2005
92. and Hama R "Confirmed influenza A and sudden death during sleep after taking oseltamivir" 5 April 2005.
93. Rapid responses to: Symmonds M "Guidelines on neuraminidase inhibitors in children are not supported by evidence" BMJ 2004; 328: 227. Website http://bmj.bmjjournals.com accessed on 1 June 2005.
94. Shiraishi K et al. "High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza" J Infect Dis 2003; 188: 57-61.
95. Schilling M et al. "Emergence and transmission of amantadine-resistant influenza A in a nursing home" J Am Geriatr Soc 2004; 52: 2069-2073.
96. Kiso M et al. "Resistant influenza A viruses in children treated with oseltamivir: descriptive study" Lancet 2004; 364: 759-765 + (letters) 364: 733-734.
97. Gubavera LV et al. "Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus" J Infect Dis 1998; 178: 1257-1262.
98. Office fédéral de la santé publique "Recommandations pour la prévention de la grippe" Supplementum XIII, August 2000, Berne: 18 pages.
99. Zimmerli S and Mühlemann K "La prévention de la grippe aujourd'hui" Bulletin des Médecins Suisses 2001; 82 (39): 2071-2076.
100. National Institute for Clinical Excellence" Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza" Technology Appraisal no 67 September 2003, London: 32 pages.
101. Uhnoo I et al. "Treatment and prevention of influenza: Swedish recommendations" Scand J Infect Dis 2003; 35 (1): 3-11.
102. Centers for Disease Control and Prevention "Influenza antiviral medications: 2004-05 Interim chemoprophylaxis and treatment guidelines" Guidelines and recommendations, November 2004: 3 pages.
103. Langley JM et al. "Prevention of influenza in the general population: recommendation statement from the Canadian task force on preventive health care" CMAJ 2004; 171 (10): 1169-1171.
104. Ministère de la santé, de la famille et des personnes handicapées - Direction générale de la santé "Avis du conseil supérieur d'hygiène publique de France relatif à la prophylaxie chez les personnel à risque lors d'une épidémie de grippe dans une collectivité, en période de circulation du virus grippal" 16 January 2004: 6 pages.
105. Wutzler P et al. "Antiviral treatment and prophylaxis of influenza in primary care: German recommendations" J Clin Virol 2004; 31: 84-91.
106. Centers for Disease Control and Prevention "Infection control measures for preventing and controlling influenza transmission in long-term care facilities" Guidelines and recommendations, June 2005: 5 pages.
107. Ministère de la santé, de la famille et des personnes handicapées - Direction générale de la santé "Conduite à tenir devant un cas d'influenza aviaire à risque établi de transmission humaine" 3 February 2004: 17 pages.
108. Longini IM et al. "Containing pandemic influenza with antiviral agents" Am J Epidemiol 2004; 159: 623-633.
109. World Health Organization "WHO Guidelines on the use of vaccines and antivirals during influenza pandemics" 2004, Geneva: 51 pages.
110. Department of Health "UK health departments' influenza pandemic contingency plan" March 2005: 137 pages.
111. Prescrire Rédaction "Arrêts de commercialisation - Roflualo" Rev Prescrire 1994; 14 (139): 213-214.
112. Prescrire Rédaction "rimantadine - Roflualo" Rev Prescrire 1988; 8 (74): 170-172.
113. "Rimantadine". In: "Martindale The complete drug reference" 34th ed., The Pharmaceutical Press, London 2005: 653.
114. Hirji Z et al. "Utility of zanamivir for chemoprophylaxis of concomitant influenza A and B in a complex continuing care population" Infect Control Hosp Epidemiol 2002; 23 (10): 604-608.
115. Chan PKS "Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997" Clin Infect Dis 2002; 34 (suppl. 2): 58-64.
116. Hien TT et al. "Avian influenza A (H5N1) in 10 patients in Vietnam" N Engl J Med 2004; 350 (12): 1179-1188.
117. Belshe RB et al. "Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection" J Virol 1988; 62: 1508-1512.